Can-Fite A3AR Agonists Show Promise in HCC, Pancreatic Cancer, MASH
CANF•Can-Fite published a peer-reviewed Biomolecules Journal article showing its A3AR agonists Piclidenoson and Namodenoson have therapeutic activity in hepatocellular carcinoma, pancreatic cancer, MASH, liver fibrosis, autoimmune and neurodegenerative diseases. The review aggregates independent global research data and supports Can-Fite’s plan to leverage its platform technology across multiple high-value indications.
1. Peer-Reviewed Article
Can-Fite published a peer-reviewed scientific article in Biomolecules Journal reviewing the molecular signaling and clinical translation of A3 adenosine receptor agonists Piclidenoson and Namodenoson.
2. Broad Therapeutic Evidence
The article compiles data on A3AR agonist activity in solid tumors (hepatocellular carcinoma, pancreatic cancer), metabolic liver diseases (MASH, fibrosis), autoimmune and inflammatory conditions, neurodegenerative disorders, obesity and rare genetic diseases.
3. Platform Strategy Validation
By integrating findings from independent global research groups, the publication validates Can-Fite’s A3AR platform and supports its strategy to advance Piclidenoson and Namodenoson across multiple high-value markets.
4. Ongoing Clinical Trials
Namodenoson is in Phase 3 for hepatocellular carcinoma, Phase 2 for pancreatic cancer and Phase 2b for MASH, while Piclidenoson is in pivotal Phase 3 for psoriasis, underlining the immediate clinical relevance of the reviewed data.
